Leveraging large-scale multi-omics to identify therapeutic targets from genome-wide association studies

Authors: Samuel Lessard¹, Michael Chao¹, Kadri Reis², FinnGen, Estonian Biobank Research Team, Mathieu Beauvais³, Deepak K. Rajpal^{4a,5}, Srinivas Shankara¹, Jennifer Sloane⁶, Priit Palta², Katherine Klinger⁷, Emanuele de Rinaldis¹, Shameer Khader^{1*}, Clément Chatelain^{1*}

- 1. Precision Medicine & Computational Biology, Sanofi US, Cambridge, MA, USA
- 2. Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
- 3. Digital R&D Data & Computational Sciences, Sanofi, Chilly-Mazarin, France
- 4. Translational Sciences, Sanofi US, Framingham, MA, USA
- 5. Pre-Clinical and Translational Sciences, Takeda, MA, USA
- 6. Immunology & Inflammation Development, Sanofi US, Cambridge, MA, USA
- 7. Genetics Research, Sanofi US, Cambridge, MA, USA
- a. Employee of Sanofi US at the time of study

*These authors contributed equally

Corresponding author

Name	Samuel Lessard
Address	Sanofi
	Cambridge, MA, USA
E-mail	Samuel.lessard@sanofi.com

ABSTRACT

1	BACKGROUND: Therapeutic targets supported by genetic evidence from genome-wide association
2	studies (GWAS) show higher probability of success in clinical trials. GWAS is a powerful approach to
3	identify links between genetic variants and phenotypic variation; however, identifying the genes driving
4	associations identified in GWAS remains challenging. Integration of molecular quantitative trait loci
5	(molQTL) such as expression QTL (eQTL) using mendelian randomization (MR) and colocalization
6	analyses can help with the identification of causal genes. Careful interpretation remains warranted
7	because eQTL can affect the expression of multiple genes within the same locus. METHODS : We used a
8	combination of genomic features that include variant annotation, activity-by-contact maps, MR, and
9	colocalization with molQTL to prioritize causal genes across 4,611 disease GWAS and meta-analyses
10	from biobank studies, namely FinnGen, Estonian Biobank and UK Biobank. RESULTS : Genes identified
11	using this approach are enriched for gold standard causal genes and capture known biological links
12	between disease genetics and biology. In addition, we find that eQTLs colocalizing with GWAS are
13	statistically enriched for corresponding disease-relevant tissues. We show that predicted directionality
14	from MR is generally consistent with matched drug mechanism of actions (>78% for approved drugs).
15	Compared to the nearest gene mapping method our approach also shows a higher enrichment in
16	approved therapeutic targets (risk ratio 1.38 vs 2.06). Finally, using this approach, we detected a novel
17	association between the IL6 receptor signal transduction gene IL6ST and polymyalgia rheumatica, an
18	indication for which sarilumab, a monoclonal antibody against IL-6, has been recently approved.
19	CONCLUSIONS: Combining variant annotation and activity-by-contact maps to molQTL increases
20	performance to identify causal genes, while informing on directionality which can be translated to
21	successful target identification and drug development.

22 **KEYWORDS:** Genome-wide association study; molecular quantitative trait loci; causal inference;

23 therapeutic targets; interleukin 6; polymyalgia rheumatica; mendelian randomization

24 BACKGROUND

25 Genome-wide associations studies (GWAS) have been successful in identifying genes associated with

traits, diseases, and molecular phenotypes. [1, 2] Discoveries from GWAS have increased substantially

over the years due to low cost of genomic profiling technologies, an increased number of studies, larger

28 cohorts, and meta-analyses, as well as the formation of deeply phenotyped datasets.[3] The later

include large-scale biobank projects such as UK Biobank (UKB)[4, 5], Estonian Biobank[6], and

30 FinnGen. [7] As an example, the UK Biobank alone has contributed to over 3,200 publications

31 (https://www.ukbiobank.ac.uk/enable-your-research/publications), and the FinnGen project is set to

32 increase the number of discoveries emerging from rare variants enriched in the Finnish population.[7]

33 Similarly, the Estonian Biobank, with its extensive dataset, has enhanced rare and low-frequency genetic

34 variation discoveries.[8-10]

35 Discoveries from genetic studies provide a highly valuable resource for drug discoveries. For example, 36 therapeutic targets with genetic support are >2 times more likely to succeed in clinical trials.[11, 12] A 37 notable example is the association between a loss-of-function missense variant in IL23R gene and 38 Crohn's disease, suggesting that IL-23 blockage could be beneficial. [13-16] Drugs targeting the IL-23 39 receptor including Ustekinumab and Risankizumab have recently been approved by the FDA for the 40 treatment of Crohn's disease following successful clinical trials. [17-19] Other notable examples of 41 targets supported by GWAS include IL6R for rheumatoid arthritis (Sarilumab, Tocilizumab) and HMGCR 42 for high levels of low-density lipoprotein (statins).[20, 21]

While these examples clearly show that disease-associated genetic information is important for drug
development, it remains a challenge to accurately assign causal genes driving disease risk from GWAS as

most variants identified in GWAS fall in non-coding regions of the genome.[22-24] While it's been
observed that the nearest gene often is the causal gene, this is not a guarantee as genetic variants can
influence traits over large genomic distances.[25] In addition, this observation may be biased towards
genes that have been well-characterized because they fall at the center of genetic association
signals.[26]

50 Several approaches have been used to predict causal genes, including selecting the nearest gene, variant 51 pathogenicity predictions, epigenetic interactions, and integration of molecular quantitative trait loci 52 (molQTL) such as expression QTL (eQTL). Mendelian randomization (MR) integrating GWAS and molQTL 53 can help identify causal relationships while informing on directionality but may be confounded due to 54 linkage disequilibrium (LD). [27-29] On the other hand, colocalization approaches can be used to detect 55 whether molQTL and GWAS signals share a common causal variant in a specific locus. [30, 31] While 56 colocalization approaches can link genetic variation to changes in gene expression in specific tissue or 57 cell-type contexts, they also tend to be pleiotropic and often impact the expression of multiple genes 58 within the same locus. [26, 32, 33] They can also impact expression across multiple tissues and cell 59 types, decreasing their utility to identify pathogenic cell types. [32, 34, 35] In addition, a large fraction of 60 GWAS loci don't show eQTL signals, potentially due to the unavailability of data for relevant cell types or 61 specific biological contexts or variants affecting disease risk due to different mechanisms such as 62 splicing.[32, 36, 37] Despite these challenges, eQTL have successfully been used to identify causal 63 genes.[38, 39]. In addition, recent prioritization approaches such as the Locus to Gene (L2G) scores from 64 Open Targets have shown that incorporating molecular trait information does increase performance to 65 identify relevant genes. [26]

Here, we sought to use currently available eQTL information to identify disease relevant genes in the
context of drug discovery. We first derived a simple approach to prioritize causal genes based on
MR[40], eQTL colocalization[31], activity-by-contact (ABC) enhancer-promoter interactions[41], and

69 variant annotations[42]. We used this combinatorial approach as a way to mitigate the pleiotropic

- 70 effect of eQTL while retaining important information about directionality. We show that this approach
- enriches for gold standard genes[26] and captures known target biology. In addition, genes prioritized
- 52 by this approach are enriched for drug targets with successful clinical trials, and directionality inferred
- by MR or coding variants recapitulate drug mechanisms of action (MoA). Finally, we show that this
- approach can be used to identify drug indication expansion opportunities using genes related to the IL6-
- 75 R as a case study and identify a novel association between *IL6ST* and polymyalgia rheumatica.

76

77 METHODS

78 Estonian Biobank GWAS

The Estonian Biobank (EstBB) is a population-based biobank with 200k participants. The 198k data
 freeze was used for the analyses described here. All biobank participants have signed a broad informed

81 consent form.

82 All EstBB participants have been genotyped at the Core Genotyping Lab of the Institute of Genomics,

83 University of Tartu, using Illumina Global Screening Array v1.0 and v2.0. Samples were genotyped and

84 PLINK format files were created using Illumina GenomeStudio v2.0.4. Individuals were excluded from the

- analysis if their call-rate was <95% or if sex defined based on heterozygosity of X chromosome did not
- 86 match sex in phenotype data. Before phasing and imputation, variants were filtered by call-rate <95%,

87 HWE p value 2<12. Variant positions were

- 88 updated to b37 and all variants were changed to be from TOP strand using GSAMD-24v1-
- 89 0_20011747_A1-b37.strand.RefAlt.zip files from https://www.well.ox.ac.uk/~wrayner/strand/ webpage.
- 90 Chip data pre-phasing was done using Eagle v2.3 software [43] (number of conditioning haplotypes
- 91 Eagle uses when phasing each sample was set to:-Kpbwt=20000) and imputation was done using Beagle

92 v.28 Sep18.7932 [44] with effective population size ne^[2]=^[2]20,000. Population specific imputation

93 reference panel of 2297 WGS samples was used.[44]

94 FinnGen

95 The FinnGen study (https://www.finngen.fi/en) was described previously.[7] The study is a public-

96 private research project that combines genetic and healthcare data of over 500,000 Finns. The objective

97 of the FinnGen study is to identify novel medical and therapeutical insight into human diseases. It is a

98 pre-competitive partnership of Finnish biobanks, universities and university hospitals, international

99 pharmaceutical industry partners, and Finnish biobank cooperative (FINBB). A full list of FinnGen

100 partners is published here: https://www.finngen.fi/en/partners.

101 Disease GWAS processing

102 We retrieved GWAS results from FinnGen release 10 (R10), UK Biobank pan meta-analysis[45], and a

103 meta-analyses between FinnGen, UK Biobank, and Estonian biobank. For simplicity, we use the term

104 GWAS to refer to both single study GWAS and meta-analyses throughout the manuscript. In total, we

included 4,611 GWAS with at least one variant with $P < 1 \times 10^{-6}$. When appropriate, we lifted over variants 105

106 from hg38 to hg19 using the liftOver R package[46]. Variant with a minor allele frequency (MAF) <

107 0.0001 were excluded from the analysis. For each GWAS, we considered genes located within 250kb of a

108 variant with $P < 1 \times 10^{-6}$ for further analysis. For gold standard and clinical trial enrichment analyses

(described below), only genome-wide significant loci were included ($P < 5 \times 10^{-8}$). We excluded the human 109

110 leukocyte antigen (HLA) region in all analyses.

111 Disease EFO mapping

112 In order to perform semantic integration of genetic data and clinical trial data, the ontological system 113

Experimental Factor Ontology (EFO) was used. We used the EFO to map traits to their corresponding

114	EFO categories and when multiple EFO terms could be mapped to the same trait, we assigned the trait
115	to each possible term. We used the EFO version 3.52.0 (<u>https://www.ebi.ac.uk/efo/</u>).
116	Variant annotation
117	We used variant effect predictor (VEP v102) [42] to annotate the impact of variants with the following
118	options:everythingofflinecheck_existing. Coding variants were defined as those impacting protein
119	coding transcript annotated as missense variant or predicted to have "high" impact. We also retrieved
120	predicted gain or loss of function (GoLoF) variants from LoGoFunc[47], and linked non-coding variants to

- genes using activity-by-contact (ABC) maps[41]. ABC scores represent the contribution of an enhancer to
- the regulation of gene, measured by multiplying the estimates of enhancer activity and three-
- dimensional contact frequencies between enhancers and promoters. ABCmax refers to variant-gene
- 124 pairs with the highest ABC score. We also retrieved disease mutations from the Human Gene Mutation
- 125 Database (HGMD) (license acquired via Qiagen, Maryland)[48]

126 Mendelian randomization & colocalization

127 We performed transcriptome wide MR using the R package TwoSampleMR [40]. When more than one 128 instrument was present, we used the inverse variant weighted approach, otherwise we used the Wald 129 Ratio approach. We considered the following exposures: protein quantitative trait loci (pQTL) from Sun 130 et al [49], and expression quantitative trait loci from Blueprint[50], eQTLGen [51] and other datasets 131 from the EBI eQTL catalogue[51-75]. In total, 110 molQTL from 26 studies were included. For each of 132 those studies, we excluded variants with a MAF < 1%. We clumped variants using PLINK[76] using the 133 options -clump-p1 1 -clump-p2 1 -clump-r2 0.01 - clump-kb 10000 and using the European ancestry 134 subset of the 1000 Genomes Project phase 3 data as reference [77]. We only considered genes 250kb 135 around significant loci in this analysis. For each QTL, independent variants with $P < 1 \times 10^{-4}$ were used as 136 instruments. For genes with significant MR results (false discovery rate < 0.05), we also performed

- 137 colocalization analysis using COLOC[31], using a region of 250kb around the local lead GWAS variant.
- 138 Harmonization between the QTL and GWAS datasets was performed using the harmonise_data function
- in the TwoSampleMR package[40]. Only autosomes were included in this analysis.
- 140 <u>Causal gene prioritization</u>
- 141 We prioritized genes as putatively causal using a combination of evidence including MR, colocalization
- 142 H4 posterior probabilities (PP) with molQTL, presence of an associated GoLoF variant[47] or other
- 143 coding variants, distance to lead variant, and enhancer-promoter ABC scores[41]. Specifically, we ranked
- 144 genes as follow:

Rank	Criteria				
Very High	Lead GoLoF variant;				
	Or				
	Colocalization (H4 PP> 80%) with molQTL of the target gene in >2 dataset; and				
	maximum ABC score for a regulatory element overlapping the lead variant				
High	Lead coding variant;				
	Or				
	Associated ($P < 1 \times 10^{-6}$) GoLoF variant;				
	Or				
	Colocalization (H4 PP> 80%) with molQTL of the target gene in >2 dataset or				
	significant MR with protein QTL (q-value < 0.05); and maximum ABC score for an				
	associated variant overlapping a regulatory element ($P < 1 \times 10^{-6}$)				
Moderate	Colocalization with molQTL of the target gene (H4 PP>80%)				
	Or				
	Significant MR with genome-wide protein QTL (q-value < 0.05)				
	Or				
	Maximum ABC score for an element overlapping the lead variant				
Or					
	Associated (<i>P</i> <1x10 ⁻⁶) coding variant				
Weak	Colocalization with molQTL of the target gene (H4 PP>30%)				
	Or				
	Nearest gene to the lead variant				
	Or				
	Maximum ABC score for an element overlapping an associated variant ($P<1x10^{-6}$)				
	Or				
	ABC link (any score) between an element overlapping the lead variant and target				
	gene				
Very weak	Significant MR with eQTL				
	Or				
	ABC link (any score) between an element overlapping the lead variant and target				

[gene
145	
146	For a given locus, we then prioritized the best gene(s) as the one with the highest rank. In case of ties,
147	we prioritized the nearest gene to lead variant if it is within the set of genes with highest scores,
148	otherwise all highest ranked genes were prioritized equally.
149	Enrichment of gold standard genes
150	We retrieved GWAS causal gene gold standards supported by functional experiments or observations or
151	expert curation from Open Targets (version 191108).[26, 78] We linked the current analysis with the
152	gold standard gene list using Ensembl gene identifiers and EFO codes. That is, for a given gene-disease
153	pair in the current analysis, we consider it a gold standard association if the gene and GWAS EFO code
154	are present in the Open Targets gold standard gene-disease set. For each indication, we filtered out
155	genes not represented in loci where a gold standard gene is located. We calculated the enrichment of
156	gold standard genes in prioritized genes by different features or rankings as described above using
157	Fisher exact tests. In addition, we calculated the precision (number of prioritized genes that are gold
158	standards over all prioritized genes), recall (number of prioritized genes that are gold standards over the
159	total number of gold standard genes), and F1 scores for each feature.
160	Single gene colocalizing cell-type eQTL enrichment
161	To identify enriched colocalizing cell types for single genes, we calculated the ratio of indications for
162	which this gene is prioritized to be causal by a given molQTL dataset (H4 PP > 80%) over the total
163	number of prioritized indications (as defined by unique EFO) for that gene. We collapsed GWAS by
164	corresponding EFO code so that a gene was only counted once per indication (and not multiple times for

- 165 GWAS of the same disease). We then compared this ratio to the fraction of prioritized indications via
- 166 colocalization of the same eQTL dataset over all prioritized indications genome wide. In other words, we

are looking for genes that show an overrepresentation of colocalizing eQTL cell types across all

168 associated indications compared to the genome-wide distribution. This corresponds to the following

- 169 contingency table:
- 170 $\sum_{i} C_{iJK}$ $\sum_{k \neq K} C_{iJk}$
- 171 $\sum_{i} \sum_{j \neq J} C_{ijK} \qquad \sum_{i} \sum_{k \neq K} \sum_{j \neq J} C_{ijk}$

172 Where C_{ijk} =1 if disease *i* colocalize with prioritized gene *j* in tissue *k* and 0 if not. *P*-values and odds ratios 173 were calculated using Fisher exact tests. False discovery rate (FDR) adjusted *P*-values < 0.05 were

174 considered significant.

175 <u>Enrichment of disease categories for single genes</u>

176 To identify enrichment disease categories for single genes, we calculated the ratio of the number of

177 GWAS where the genes is prioritized for a given EFO category over the total number of prioritized GWAS

178 for that gene. We then compared this ratio to the genome-wide ratio of GWAS for this EFO category

179 over the total number of tested GWAS. This corresponds to the following contingency table:

- 180 $\sum_i D_{iJC}$ $\sum_i \sum_{c \neq C} D_{iJC}$
- 181 $\sum_{i} \sum_{j \neq J} D_{ijC} \qquad \sum_{i} \sum_{c \neq C} \sum_{j \neq J} D_{ijC}$

182 Where D_{ijk} =1 if disease *i* is prioritized for gene *j* and belongs to category *c* and 0 if not. *P*-values and odds

183 ratios were calculated using Fisher exact tests. FDR adjusted P-values < 0.05 were considered

184 significant.

185 Disease colocalizing molQTL cell-type enrichment

We identify enriched cell types in GWAS disease EFO categories supported by colocalization as in King et al. 2021.[79] Briefly, we extracted all GWAS colocalizing molQTL (H4 probability > 0.8). Then, for a given cell type *K* and disease category *I*, we generated the following contingency table:

189 $\sum_{j} C_{IjK}$ $\sum_{j} \sum_{k \neq K} C_{Ijk}$

190
$$\sum_{j} \sum_{i \neq I} C_{ijK} \qquad \sum_{j} \sum_{k \neq K} \sum_{i \neq I} C_{ijk}$$

191 Where C_{ijk} =1 if at least one disease GWAS of category *i* colocalize with gene *j* in tissue *k* and 0 if not. *P*-192 values and odds ratios were calculated using Fisher exact tests. We performed the analysis considering 193 all molQTL separately, as well as by grouping similar cell types and tissues together prior to testing for

194 enrichment. FDR adjusted *P*-values < 0.05 were considered significant.

195 Drug target- indication pairs in clinical trials

196 Information about drugs approved or in clinical trials was obtained from the Citeline data from Informa 197 Pharma Intelligence, which is a superset of the most used data sources. In addition to multiple data 198 streams, including nightly feeds from official sources such as ClinicalTrials.gov, Citeline also contains 199 data from primary sources such as institutional press releases, financial reports, study reports, and drug 200 marketing label applications, and secondary sources such as analyst reports by consulting companies. 201 Secondary sources are particularly important to reduce potential biases to the organizations' tenancy to 202 report only successful trials, especially those before the FDA Amendments Act of 2007, which requires 203 all clinical trials to be registered and tracked by ClinicalTrials.gov. Citeline database contains information 204 from both US and non-US sources. Any cancer or cancer related indications were excluded from this 205 analysis.

In order to map gene-disease pairs in the genetic data to target-indication pairs in the drug data, we
 used experimental factor ontology (EFO), which provided a systematic description of many data

208 elements available in EBI databases. A target-indication pair is said to have genetic evidence if there is 209 genetic evidence of association between the gene and disease sufficiently similar to the indication, 210 based on semantic similarity. Two methods were used to calculate semantic similarity matrix. [80, 81] 211 Semantic similarities between each pair of EFO headings were computed in the ontologySimilarity R 212 package. [82] The average of the two methods was calculated and standardized similarities had a 213 maximum value of 1 for each disease or indication. Two diseases are considered similar if the similarity 214 is greater than or equal to a previously published value of 0.7.[11] 215 Prediction of drug mechanism of action directionality 216 We retrieved information about drug mechanism of action from the Informa Pharma Intelligence 217 dataset described above. For targets for which *decreased* expression or loss of function (LoF) is 218 beneficial, we considered datasets with the following keywords: "antagonist", "inhibitor", and 219 "degrader". For targets for which increased expression or function is beneficial, we considered the 220 following keyworks: "agonist", and "activator". We considered drugs and targets in phase II clinical trial 221 or above. We performed two analyses to infer directionality from GWAS. First, we assess directionality 222 using the effect size of low-frequency lead coding variant (MAF < 5%). We assumed that these variants 223 are disruptive or LoF. Therefore, a LoF coding variant associated with increased risk suggests that a drug 224 MoA of agonist or activator would be beneficial, whereas for a protective LoF coding variant, an 225 inhibitor or antagonist would be beneficial. Next, we assessed directionality based on the direction of 226 effect of gene expression on disease risk predicted by MR using molQTL as exposure (q-value < 0.05). 227 We included only molQTL colocalizing with local GWAS signal (H4 PP > 80%). For gene-disease pairs 228 supported by multiple colocalizing molQTL, a consensus direction was inferred if the MR direction of 229 effect was consistent across > 75% of the molQTL. Here, a negative consensus MR direction suggests 230 that increased gene expression leads to decreased disease risk. Therefore, an activator or agonist drug

targeting this gene would be beneficial. Conversely, a positive consensus MR direction suggests that

232	increased gene expression increases disease risk, and an inhibitor or antagonist drug would be
233	beneficial. We calculated enrichment of concordant direction of effect between GWAS and drug MoA
234	using Fisher exact tests.
235	Identification of causal links between diseases and genes related to the IL6 receptor
236	We aimed to apply our proposed approach to a specific case example. Using the causal gene
237	prioritization and GWAS datasets described above, we extracted all disease GWAS for which IL6, IL6R, or
238	IL6ST were predicted to be causal. We predicted directionality of effect of gene expression on disease
239	risk by MR as above using a threshold of q-value < 0.05. We generated local association of plots molQTL
240	and GWAS using LocusZoom[83]. We performed fine-mapping of <i>IL6ST</i> genetic variants associated with
241	polymyalgia rheumatica using SuSIE[84] as previously described for FinnGen[7].
242	
243	RESULTS
244	Prioritization of putative causal genes in thousands of GWAS

245 We aimed to prioritize causal genes across 4,611 GWAS from 3 different sources (Table 1): UK Biobank 246 (UKB)[45], FinnGen release 10 (R10), and meta-analyses of UK Biobank, FinnGen R10, and Estonian 247 biobank. [6] For simplicity, we refer to both single studies and meta-analyses as GWAS throughout the 248 manuscript. While molecular QTLs (molQTL) such as expression quantitative trait loci (eQTL) have been 249 used previously to prioritize causal genes, they are often pleiotropic with the same variant associated 250 with multiple genes within the same locus. [26, 32, 33] Additional genomic information such as the ABC 251 model have been shown to increase performance to identify causal genes, in particular when selecting 252 genes with the highest ABC score (ABCmax).[41] Therefore, we derived a ranking scheme to prioritize 253 genes using different features including ABC, molQTL, presence of an associated coding or gain or loss of

254 function (GoLoF) variants, and distance to lead variant (Figure 1A, methods). We integrated 110 molQTL 255 datasets from 26 studies using MR to infer causality and directionality of gene expression on disease 256 risk. We also performed colocalization analysis to confirm that both GWAS or meta-analyses and molQTL 257 signals shared at least one causal variant. Top ranking genes were selected as those that either 258 contained an associated lead coding variant or were supported by both ABCmax and colocalization 259 across >2 cell types or tissues. We did not include distance to lead variant for higher ranks because we 260 wanted to first prioritize genes for which we could identify potential biological mechanisms. However, 261 for loci without such evidence, or in cases where multiple genes showed identical ranks, the nearest gene to the lead variant was selected as the putative causal gene if it was among the best candidates. 262 263 Overall, between 1.1 and 1.4 genes were prioritized per locus (before breaking ties with the nearest 264 gene), with 17-49% of loci supported by molQTL colocalization or coding variants (Table 1).

265 Enrichment of genomic features for gold standard genes

266 Comparing the enrichment of different genomic features alone for curated gold standard genes[26], we 267 found a strong enrichment for genes supported by ABCmax with lead variant (Odds ratio (OR)=8.0-18.7, P=0.0002-4x10⁻⁶) (Additional file 1: Figure S1; Additional file 2: Table S1). molQTL colocalization also 268 269 enriched for gold standard genes (colocalization H4 posterior probability (PP) > 95%, OR=3.4-17.7, 270 $P=0.001-2x10^{-12}$). However, the strongest enrichment was generally observed for genes with associated lead coding variants[47] (OR>36.2, $P=0.0002-2x10^{-10}$) and the nearest gene (OR=17.7-38.7, $P=3x10^{-9}$ -271 272 1×10^{-25}). The strong enrichment for nearest genes is expected given that the gene closest to the lead 273 variant is often the causal gene. In addition, several of the gold standard genes have been selected 274 because they are supported by coding variants or tend to fall in the center of GWAS peaks and have 275 been investigated more closely[26]. However, when using these features in combination, we found that 276 our ranking approach performed well and generally better than selecting the nearest gene alone, with a

- 277 mean increase in F1 score of 0.08 (-0.03 0.23) (Additional file 1: Figure S2-S3; Additional file 2: Table
 278 S1).
- 279 Gain and Loss of function variants identify genes linked to monogenic disorders
- 280 Integrating information about GoLoF variants retrieved variants linked to monogenic disorders including
- 281 *PSEN1* with Alzheimer's disease (AD)[85] (rs764971634, p.lle437Val, *P*=2x10⁻¹²), *SQSTM1* and Paget's
- disease[86] (rs104893941, p.Pro392Leu, P=6x10⁻¹¹), and HFE and disorders of iron metabolism[87]
- (rs1800562, p.Cys282Tyr, P=1x10⁻¹⁷⁸) (Figure 1B; Additional file 2: Table S3). We also identified
- protective GoLoF variants such as APP p.Ala673Thr (rs63750847, P=7x10⁻¹¹) reducing odds of developing
- AD[88], and ALOX15 p.Thr560Met protecting against nasal polyps (rs34210653, P=2x10⁻¹⁵)[89]. Of 208
- 286 genes prioritized with at least one predicted GoLoF variant, 179 had at least one disease mutation
- reported in the Human Gene Mutation Database (HGMD)[48] (OR = 2.3 [1.5-3.6], *P*=5x10⁻⁶). Potential
- novel associations included *COLGALT2* and arthrosis (rs35937944, p.Tyr212Cys, *P*=2x10⁻¹⁴), *LRG5* and
- 289 carcinoid syndrome (rs200138614, p.Cys712Phe, *P*=4x10⁻⁹), and *GREB1* and female infertility
- 290 (rs755857714, p.Arg1339His, *P*=4x10⁻⁹).
- 291 Colocalizing molQTL link genes to diseases and pathogenic tissues

292 Prioritized candidate causal genes showed enrichment in disease colocalizing molQTLs related to their 293 known function. For instance, colocalizing molQTL for prioritized genes supported associations with disease categories such as EDNRA, LPA and FGF5 with cardiovascular diseases (P<2x10⁻¹⁶), TSLP, IL33 and 294 CHRNA3 and respiratory system diseases (P<7x10⁻²¹), and II23R, TYK2, IL10 and immune system disease 295 296 (P<5x10⁻¹¹) (Figure 1C-D; Additional file 2: Table S4). In addition, we found an enrichment of disease 297 colocalizing eQTLs in kidney cortex for FGF5, a gene expressed during kidney development and associated with kidney function ($P=4x10^{-15}$)[90] (Figure 1E; Additional file 2: Table S5). Other examples 298 include artery eQTLs for the cardiovascular diseases associated gene PHACTR1[91] ($P=1\times10^{-9}$); the 299

300	lysosomal acid lipase (LIPA) gene and microglia eQTLs ($P=1x10^{-10}$); and the ABO with plasma pQTL
301	($P=1x10^{-20}$). Finally, we confirmed that enriched colocalizing eQTLs matched the expected pathogenic
302	tissues and cell-types of different disease categories (Figure 1F; Additional file 2: Table S6). For instance
303	after grouping eQTL of similar tissues and cell types together, we found a strong enrichment of genes
304	with artery and heart eQTL colocalizing with cardiovascular disease GWAS (P < 9 <x10<sup>-17). We found</x10<sup>
305	similar enrichment for T cell and thyroid eQTLs in endocrine system diseases (P <3x10 ⁻⁸); blood,
306	lymphoblastoid cell line, monocytes, neutrophil, and T cells with immune system diseases (P <4x10 ⁻⁶);
307	and fibroblasts and musculoskeletal diseases (P <4x10 ⁻⁶). Treating each eQTL data separately revealed
308	additional associations with tissues or cell subsets including brain cortex and diseases of the visual
309	system (P <6x10 ⁻⁶); cerebellum and nervous system diseases (P <4x10 ⁻⁶); regulatory T cells and endocrine
310	system diseases (P <9x10 ⁻⁹); and T helper 17 cells and digestive system diseases (P <5x10 ⁻⁷) (Additional
311	file 1: Figure S4; Additional file 2: Table S7). Overall, the analyses illustrate that in contrast to the
312	nearest gene approach, inclusion of eQTL can help identify potential pathogenic cell types and tissues.
313	Prioritized genes increase clinical trial probability of success
314	Building on these results, we tested whether we could use molQTL information of putative causal gene
315	to drive drug repurposing opportunities or identify potential safety concerns. First, we evaluated

316 whether the prioritized genes enriched for therapeutic targets with clinical trial success. Clinical trial

317 information was retrieved from the Citeline Pharma Intelligence project. Consistent with previous

observations, we found that targets with clinical trial success were enriched for features such as

presence of coding variation (Figure 2A, Additional file 2: Table S8). For example, gain or loss of

320 function lead variants demonstrated some of the best predictive performances, in particular using

321 genetic evidence from the UKB EUR ICD10 (Phase I: Risk ratio (RR)=1.23, P=0.104; Phase II: RR=1.33,

- 322 *P*=0.0688; Phase III: RR=2.08, *P*=0.0023; Approved: RR=2.67, *P*=0.00378). Similar results were observed
- 323 across all studies. Use of epigenetic evidence also improved predictions, for example, lead SNPs linked

324	by the ABC model in UKB EUR ICD10 (Phase I: RR=1.33, P=0.00484; Phase II: RR=1.4, P=0.0162; Phase III:
325	RR=2.15, P=0.000304; Approved: RR=2.82, P=0.000622). However, molQTL information alone did not
326	enrich as much for clinical trial success, for example, colocalizing molQTL with posterior probability >
327	80% in UKB EUR ICD10 (Phase I: RR=1.22, P=0.013; Phase II: RR=1.18, P=0.154; Phase III: RR=1.43,
328	P=0.0581; Approved: RR=1.71, P=0.044). While the overall prioritized genes did not show the strongest
329	enrichment (UKB ICD10 Phase I: RR=1.24, <i>P</i> =0.0006; Phase II: RR=1.17, <i>P</i> =0.0.08; Phase III: RR=1.51,
330	P=0.003; Approved: RR=1.60, $P=0.03$), this was likely due to the inclusion of genes with no supportive
331	evidence other than distance (Figure 2A). Indeed, we found that "High" and "Very High" prioritization
332	ranks were more predictive of successful clinical trial progression (higher risk ratios) than lower-ranking
333	genes, especially at later clinical trial phases or approval (High + Very high ranks in UKB ICD10 Phase I:
334	RR=1.16, <i>P</i> =0.103; Phase II: RR=1.18, <i>P</i> =0.174; Phase III: RR=1.78, <i>P</i> =0.00149; Approved: RR=2.06,
335	P=0.00637) (Figure 2B; Additional file 2: Table S9). In our analysis, distance itself was seldom predictive
336	or clinical trial success (UKB ICD10 Phase I: RR=1.18, P=0.03; Phase II: RR=1.06, P=0.0.61; Phase III:
337	RR=1.24, P=0.61; Approved: RR=1.38, P=0.19) especially after excluding loci potentially driven by coding
338	variants (Figure 2B).
339	Inferred directionality from GWAS recapitulate drug mechanisms of action
340	To understand whether inferred directionality could inform on clinical trial success, we first investigated
341	the consistency between the direction of effect of coding variants and drug mechanism of action (MoA)
342	(methods). When considering prioritized genes with lead low-frequency coding variants (minor allele
343	frequency < 0.05) and clinical trials phase II and above, between 83% and 96% of showed consistent

effect between the minor allele and drug MoA (Fisher $P=0.08-6x10^{-8}$, Figure 2C). We then asked whether

345 molQTL could similarly inform on directionality. Using prioritized gene-disease pairs supported by MR (q-

- value < 0.05) and colocalization (PP > 80%), we inferred the direction of effect when the predicted MR
- 347 effect was consistent across >75% of molQTL datasets for a given gene. This was the case for most gene-

348	disease pairs (Additional file 1: Figure S5). Again, direction of effect was generally in agreement with
349	drug MoA (64-81% agreement, Fisher $P=4x10^{-8}-5x10^{-41}$, Figure 2D). Consistency increased when
350	considering only approved drugs (78-93% agreement, Fisher $P=3 \times 10^{-5}-1 \times 10^{-23}$, Additional file 1: Figure
351	S6). Overall, these data suggest that molQTL can be used to inform on drug MoA.

352 Causal gene predication from GWAS identifies a link between IL6ST and polymyalgia rheumatica

353 Finally, we applied our causal gene prioritization approach to a specific use case, that is identifying 354 potential new indications for drugs targeting the IL6 receptor such as Sarilumab and Tocilizumab, both 355 drugs approved for rheumatoid arthritis. We extracted diseases prioritized by our approach for genes 356 related to the receptor, namely IL6, IL6ST, and IL6R. We identified putative causal links between 357 increased *IL6* expression in CD16 monocytes and increased risk of varicose veins, ischemic heart disease, 358 coronary atherosclerosis, and atrial fibrillation (MR beta > 0), but decreased risk of asthma and allergy 359 (MR beta < 0) (Additional file 1: Figure S7; Additional file 2: Table S10). eQTL of *IL6* in whole blood also 360 supported these disease associations, albeit with an opposite predicted direction of effect. Similarly, 361 *IL6R* expression in multiple tissues including artery, colon, and esophagus was associated with increased 362 risk of coronary revascularization, coronary atherosclerosis, and abdominal aortic aneurysm (AAA), but 363 lower risk of lower respiratory diseases and atopic dermatitis. Again, we observed opposite direction of 364 effect predicted by MR using monocyte or macrophage eQTL as exposure. The associations with 365 coronary atherosclerosis and AAA were further driven by a lead coding variant in *IL6R*, rs2228145 366 (Asp358Ala, Additional file 2: Table S10). Finally, we found that increased IL6ST expression in T cells and 367 whole blood is predicted to increase the risk of rheumatoid arthritis, systemic connective tissue 368 disorders, polyarthropathies, other arthritis, autoimmune diseases, and polymyalgia rheumatica (Figure 369 3A). The later association has not been reported previously to our knowledge. These associations were 370 driven by rs7731626 (SuSIE fine-mapping probability >0.99). This variant is located within an intron of 371 ANKRD55 and colocalizes with eQTLs for both ANKRD55 and IL6ST (PP > 80%). However, this variant also

overlaps an enhancer that shows highest ABC score for *IL6ST* for genes in the region, suggesting the
latter is the causal gene, in line with previous studies[92, 93] (Figure 3B). Overall, our approach was able
to capture known associations with IL6-R related genes and identified a new association between *IL6ST*and polymyalgia rheumatica.

376

377 DISCUSSION

378 We prioritized disease-associated genes across 4,611 GWAS and meta-analyses from biobank studies 379 using a combination of MR with molQTL, colocalization analysis, variant effect prediction, and epigenetic 380 annotations (ABC model). This approach allows the use of molQTL to infer directionality of gene 381 expression on disease risk, while improving the causal gene prediction compared to using molQTL alone. 382 Based on combination of these features, we used a ranking approach to prioritize genes within loci and 383 showed that this approach enriched for gold standard genes. We recover known coding variant 384 associations, including rare variants in genes linked to monogenic disorders such as PSEN1 and APP1 and 385 Alzheimer's disease, and SQSTIM1 and Paget's disease (Figure 1B). Genes prioritized by molQTL also 386 show enrichment in disease categories related to their function with pathogenic tissue contexts (Figure 387 **1C-F**). Of note, when multiple genes show evidence of colocalization within the same locus, the addition 388 of epigenetic (ABCmax) information can help prioritize one gene over the others. We note as an 389 example the association of variants with polymyalgia rheumatica at the ANRKD55 locus where this gene 390 would be prioritized using the nearest gene approach. Whereas colocalization alone did not identify a 391 single causal gene, combination of colocalization and ABCmax identified *IL6ST* as the putative causal 392 gene. To our knowledge, this is the first report of a GWAS association between *IL6ST* and polymyalgia 393 rheumatica. *IL6ST* encodes a protein involved in signal transduction for the IL6 receptor pathway.

Inhibitors of the IL6 receptor have recently shown success in clinical trials for this indication leading to a
 recent approval by the FDA.[94]

396 In line with previous studies [11, 12], we show that therapeutic targets with genetic evidence are 397 enriched at later clinical trial phases and as targets of approved drugs. In our analysis, using the nearest 398 gene information alone was not strongly predictive of clinical trial success. The most predictive features 399 were coding variant annotations and ABC maps. While the later performs well to link causal genes to 400 diseases, it does not provide information about directionality. We used coding variants and MR with 401 molQTL to infer directionality of a target on disease risk. Both approaches were generally consistent 402 with drug MoA matched for the target and disease. These data support that molQTL can be used to 403 predict drug MoA. However, while we found that in general eQTL were consistent across cell type and 404 tissues for a given gene and disease (Additional file 1: Figure S5), we note that this isn't always the case. 405 This is exemplified by the IL6-R case study, where all three queried gene displayed inconsistent direction 406 of effect predicted by MR depending on the molQTL dataset. Future improvement of this approach 407 should consider prior knowledge on pathogenic cell types or tissues to infer directionality in relevant 408 contexts. Overall, our analysis suggests that using features such as ABCmax in combination to molQTL 409 can increase the performance of causal gene inference approaches while informing on directionality 410 which is crucial for translating GWAS hits to therapies.

We note that this study has some limitations. First, we did not perform fine-mapping analyses nor colocalization approaches that use linkage disequilibrium references. Indeed, we opted to avoid methods that do not rely on LD references as we used GWAS from various sources, including metaanalyses where these methods may not be well calibrated. [95] Nevertheless, using fine-mapping information likely would improve performance, especially in cases where there are multiple causal variants underlying molQTL or GWAS signals, and would reduce LD contamination[30, 96]. In addition, we performed MR and colocalization analyses as separate steps. Tools that use a combination of these

418	approaches have been recently developed, which are likely to perform better in case of allelic
419	heterogeneity[97]. This is evident in the case of <i>IL6ST</i> , where MR using eQTL from whole blood from
420	different sources (GTEx, eQTLGen) lead to inversed estimate of directionality (Figure 3A). This difference
421	was due to different instrument used as only one genetic instrument was included in GTEx whereas 5
422	independent instruments were included for eQTLGen. We also assume that there is one causal gene per
423	locus, although it is possible that multiple genes contribute to disease risk. Finally, integrating other
424	sources of molQTL such as metabolite or splice QTL could help identify putative causal genes as coding
425	variants and eQTL only cover a fraction of loci (18-45% in this study).[98] While these approaches can be
426	useful to nominate candidate causal genes and their relationship to diseases, proper functional
427	validation remains of high importance.
428	
429	CONCLUSIONS
430	We nominated putative causal genes across 4,611 GWAS from biobank studies and public resources by
431	integrating variant annotations as well as molecular QTL. We show that these prioritized genes recover
432	known biological relationships in terms of disease and tissue enrichment and are enriched for
433	therapeutic targets that succeeded in clinical trials. We show that directionality predicted by molQTL
434	and coding variants generally recapitulate drug mechanism of actions. Finally, we applied this approach
435	to genes related to the IL6 receptor and identified a novel association between <i>IL6ST</i> and polymyalgia
436	rheumatica supporting the recent approval of Sarilumab for this indication.

437

438 ABBREVIATIONS

- 439 AAA: abdominal aortic aneurysm; ABC: Activity-by-contact; CI: Confidence interval; EFO: Experimental
- 440 factor ontology; eQTL: Expression quantitative trait loci; EstBB: Estonian Biobank; GWAS: Genome-wide
- 441 association study; GoF: Gain of function; GoLoF: Gain or loss of function; HLA: Human leukocyte antigen;
- 442 iPSC: Induced Pluripotent Stem Cells; LCL: Lymphoblastoid cell lines; LD: Linkage disequilibrium; LoF:
- Loss of function; MAF: Minor allele frequency; MoA: Mechanism of action; MR: Mendelian
- randomization; molQTL: Molecular quantitative trait loci; OR: Odds ratio; pQTL: Protein quantitative
- 445 trait loci; PP: posterior probability; QTL: Quantitative trait loci; RR: Risk ratio; UKB: UK Biobank; VEP:
- 446 Variant effect predictor.

447 FIGURE LEGENDS



449 Figure 1. Characteristics of prioritized genes via gain or loss of function variants and molQTLs. A) 450 Features used to prioritize genes in GWAS loci. Genes are ranked based on a combination of features 451 including molQTLs, activity-by-contact (ABC) maps, and variant annotations, including variant effect 452 predictions (VEP) and loss-of-function (LoF) and gain-of-function (GoF) predictions. B) Disease-453 associated predicted GoF and LoF variants captures disease associations with high effect sizes. Lead GoF and LoF variant with GWAS *P*-value $< 5 \times 10^{-8}$ are reported in the figure. Effect of the risk allele (odds 454 455 ratio) is reported on the y-axis. The x-axis corresponds to the frequency of the risk allele. C) Disease 456 category overrepresentation for single genes predicted to be causal. Each dot represents a different 457 associated disease category. Top 30 enrichments are shown. D) Same as B, but filtered for genes 458 predicted to be causal and enriched in "Immune system diseases". Each dot represents a different 459 associated disease category. Top 30 genes are shown. E) Overrepresentation of eQTL colocalization for 460 single genes predicted to be causal. Gene-tissue pairs are included only if the gene has the highest rank 461 in a locus for a given associated disease. Top 30 colocalized eQTLs are shown. Each dot represents a 462 different enriched tissue or cell-type. F) Enriched colocalizing cell types and tissues by disease 463 categories. Only disease categories and tissues or cell types with at least one significant enrichment are 464 reported in the heatmap. Enrichment P-values are calculated using Fisher exact test, testing for the 465 enrichment of genes with eQTL colocalizing with GWAS belonging to specific disease categories as in 466 [79]. Tissues and cell-types were collapsed into broader categories before testing for enrichment. For 467 example, tibial, coronary, and aorta arteries were grouped into "artery". 468 molQTL: Molecular QTL; ABC: Activity-By-Contact; LCL: Lymphoblastoid cell lines; iPSC: induced 469 **Pluripotent Stem Cells**

470 .: Adjusted P<0.1; *: Adjusted P<0.05; **: Adjusted P<0.01; ***: Adjusted P<0.001





481 (MoA) for targets in phase II clinical trials or above. We retrieved information about targets, clinical 482 trials, and drug MoA from the Citeline Pharmacogenomics dataset. We connected this dataset to GWAS 483 phenotypes using EFO codes and a semantic similarity score > 0.7. We assume that low-frequency 484 coding variants (minor allele frequency < 5%) are disruptive (LoF). Therefore a negative (protective) 485 direction of effect would translate into inhibition or antagonism being beneficial (and vice-versa). D) 486 Concordance between the predicted impact of gene expression on disease risk predicted by mendelian 487 randomization (MR), and drug MoA for targets in phase II clinical trials or above. Information about 488 targets, clinical trials, and drug MoA were collected from the Citeline Pharmacogenomics dataset and 489 connected to GWAS phenotypes using EFO codes and a semantic similarity score > 0.7. The direction of 490 effect of gene expression on disease risk was assessed by MR using molQTL as exposure (q-value < 0.05). 491 Only molQTL colocalizing with local GWAS signal (H4 posterior probability > 80%) were included. A 492 consensus direction was inferred if the MR direction of effect was consistent across > 75% of molQTL for 493 a given gene and disease GWAS. A negative consensus MR direction suggests that increased gene 494 expression leads to decreased disease risk. Therefore, an activator or agonist drug targeting this gene 495 would be beneficial. Conversely, a positive consensus MR direction suggests that increased gene 496 expression increases disease risk, and an inhibitor or antagonist drug would be beneficial. Reported P-497 values were calculated by Fisher exact test.

499

498

.: P<0.1; *: P<0.05; **: P<0.01; ***: P<0.001







510 TABLES

511	Table 1. GWAS included in this study. The table reports the maximum GWAS sample size for each study,
512	the total number of GWAS with at least one associated gene. The number of loci with at least one
513	variant with GWAS $P < 1 \times 10^{-6}$ To calculate the number of loci, we defined 250kb regions each side of the
514	lead variant. Overlapping regions were then merged. The table reports the total number of non-
515	overlapping regions. The mean number of prioritized genes corresponds to the average number of
516	genes prioritized across each GWAS. The mean number of prioritized gene per locus correspond to the
517	average number of genes with the highest scores in a locus. For the analyses reported throughout this
518	manuscript, ties are broken using the shortest distance to the lead variant. Finally, the last column

reports the average number of prioritized gene supported by coding variants or molQTL colocalization.

Study ID	Max	Numbe	Mean N	Mean	Mean N	Mean N prioritized
	sample	r of	loci	N	prioritized	genes supported by
	size	GWAS	(<i>P</i> <1x10	priorit	genes per	molQTL or coding
			⁶)	ized	locus	variants
				genes		
FinnGen R10	412,181	2,297	16.36	22.86	1.18	0.22
FinnGen, UK						
biobank, Estonian						
biobank meta-	1,073,9					
analysis (R10)	98	95	123.44	183.59	1.38	0.45
UKBB pan ICD-10						
(European)	420,531	898	9.01	10.83	1.14	0.17
UKBB pan	42,0531	1,321	10.52	13.11	1.15	0.19

phecodes			
(European)			

520 molQTL: molecular QTL; N: Number

521 **DECLARATIONS**

522 <u>Ethics approval and consent to participate</u>

Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea, the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr HUS/990/2017.

The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, THL/1524/5.05.00/2020, and THL/2364/14.02/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020 and Statistics Finland (permit numbers: TK-53-1041-17 and TK-53-90-20).

The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 6 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001.

543 UK Biobank has received ethical approval from the NHS National Research Ethics Service North West 544 (approval numbers 11/NW/0382 and 16/NW/0274). All participants provided written informed consent. 545 Estonian Biobank GWAS and consecutive meta-analyses were carried out under ethical approval permit 546 number 1.1-12/1020 from the Estonian Committee on Bioethics and Human Research (Estonian Ministry 547 of Social Affairs). 548 549 Consent for publication 550 Not applicable. 551 552 Availability of data and materials 553 The UK Biobank Pan ancestry GWAS[45] are available through https://pan.ukbb.broadinstitute.org/. 554 FinnGen GWAS[7] are available through <u>https://www.finngen.fi/en/access_results</u>. Processed and 555 formatted eQTL data used in this study are available through the eQTL catalogue [52-75] 556 https://www.ebi.ac.uk/eqtl/. pQTL from Sun et al. 2018[49] are available through 557 http://www.phpc.cam.ac.uk/ceu/proteins/. eQTLGen eQTL[51] are available through 558 https://www.eqtlgen.org/phase1.html. 1000 Genomes project phase 3 data[77] is available through 559 https://www.internationalgenome.org/category/phase-3/. Activity-by-contact maps[41] are available 560 through https://www.engreitzlab.org/resources/. LoGoFunc[47] gain and loss of function predictions are 561 available through https://itanlab.shinyapps.io/goflof/. Datasets supporting the conclusions of this article are included within the article and its additional files. Additional datasets used and/or analysed during 562 563 the current study are available from the corresponding author on reasonable request. 564

565 <u>Competing interests</u>

- 566 SL, MC, MB, SS, CC, EdR, KK, JS, SK are employees of Sanofi US Services and hold shares and/or stock
- 567 options in the company. DKR is currently an employee of Takeda and was an employee of Sanofi US
- 568 Services at the time of study. All authors declare no other competing interests.

569

- 570 <u>Funding</u>
- 571 This study was funded by Sanofi (Cambridge, MA, United States). The funder had the following
- 572 involvement with the study: Sanofi reviewed the manuscript.
- 573 The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH
- 574 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc.,
- 575 Celgene Corporation, Celgene International II Sàrl, Genentech Inc., Merck Sharp & Dohme Corp, Pfizer
- 576 Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics
- 577 Inc., Janssen Biotech Inc, and Novartis AG.
- 578 UK Biobank is supported by its founding funders the Wellcome Trust and UK Medical Research Council,
- as well as the Department of Health, Scottish Government, the Northwest Regional Development
- 580 Agency, British Heart Foundation and Cancer Research UK.

Estonian Biobank research was supported by the European Union through Horizon 2020 research and
innovation programme under grant no 810645 and through the European Regional Development Fund
project no. MOBEC008, by the Estonian Research Council grant PUT (PRG1291, PRG687 and PRG184)
and by the European Union through the European Regional Development Fund project no. MOBERA21
(ERA-CVD project DETECT ARRHYTHMIAS, GA no JTC2018-009), Project No. 2014-2020.4.01.15-0012 and
Project No. 2014-2020.4.01.16-0125.

587

588 <u>Authors' contributions</u>

	589	SL, MC	, and CC	performed	data analy	/sis, inter	preted the	results, de	esigned anal	yses,	, and are ma	jor
--	-----	--------	----------	-----------	------------	-------------	------------	-------------	--------------	-------	--------------	-----

- 590 contributors in writing the manuscript. FinnGen authors defined endpoints, performed GWAS,
- 591 generated summary statistics, and performed meta-analyses. Estonian Biobank authors defined
- 592 matching disease endpoints, performed GWAS and generated EstBB summary statistics. MB acquired
- and formatted data and performed data analysis. SS, KK, EdR, JS, SK, DR designed the study, interpreted
- results, and contributed to writing the manuscript. All authors read and approved the final manuscript.

595

596 Acknowledgments

597 We thank all participants and contributors to the datasets used in this study. We thank Hao He (Sanofi

598 US) for his valuable feedback on the manuscript, and Omar Stradella (Sanofi US) for his support with

599 ontology mapping.

600 UK Biobank

This research has been conducted using the UK Biobank Resource (<u>www.ukbiobank.ac.uk</u>), a large-scale biomedical database and research resource containing genetic, lifestyle and health information from 500,000 UK participants. UK Biobank is supported by its founding funders the Wellcome Trust and UK Medical Research Council, as well as the Department of Health, Scottish Government, the Northwest Regional Development Agency, British Heart Foundation and Cancer Research UK. The UK biobank panancestry analysis was conducted under project ID 31063 (https://pan.ukbb.broadinstitute.org).

607 FinnGen

- The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH
- 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc.,
- 610 Celgene Corporation, Celgene International II Sàrl, Genentech Inc., Merck Sharp & Dohme Corp, Pfizer
- 611 Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics
- 612 Inc., Janssen Biotech Inc, and Novartis AG. Following biobanks are acknowledged for delivering biobank
- 613 samples to FinnGen: Auria Biobank (<u>www.auria.fi/biopankki</u>), THL Biobank (<u>www.thl.fi/biobank</u>), Helsinki
- 614 Biobank (<u>www.helsinginbiopankki.fi</u>), Biobank Borealis of Northern Finland
- 615 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx),
- 616 Finnish Clinical Biobank Tampere (<u>www.tays.fi/en-</u>
- 617 US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland
- 618 (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki),
- 619 Finnish Red Cross Blood Service Biobank (<u>www.veripalvelu.fi/verenluovutus/biopankkitoiminta</u>) and
- 620 Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All
- 621 Finnish Biobanks are members of BBMRI.fi infrastructure (<u>www.bbmri.fi</u>). Finnish Biobank Cooperative -
- 622 FINBB (<u>https://finbb.fi/</u>) is the coordinator of BBMRI-ERIC operations in Finland.
- 623 Estonian Biobank
- 624 Estonian Biobank research was supported by the European Union through Horizon 2020 research and
- 625 innovation programme under grant no 810645 and through the European Regional Development Fund
- project no. MOBEC008, by the Estonian Research Council grant PUT (PRG1291, PRG687 and PRG184)
- and by the European Union through the European Regional Development Fund project no. MOBERA21
- 628 (ERA-CVD project DETECT ARRHYTHMIAS, GA no JTC2018-009), Project No. 2014-2020.4.01.15-0012 and
- 629 Project No. 2014-2020.4.01.16-0125. Computations were performed in the High Performance
- 630 Computing Center, University of Tartu.

631 molQTL datasets

651

632	This manuscript makes use of previously published molecular QTL data. Except for pQTL from Sun 2018
633	and eQTL Gen, formatted summary statistics were obtained from the EBI eQTL catalogue. We wish to
634	thank all participants and contributors to these datasets. We list funding sources of each of the dataset
635	in a supplementary note.
636	Estonian Biobank and FinnGen banners
637	The Estonian Biobank team is composed of: Andres Metspalu, Mari Nelis, Lili Milani, Reedik Mägi,
638	Georgi Hudjashov, and Tõnu Esko (University of Tartu, Tartu, Estonia). FinnGen authors and their
639	institution are listed in a supplementary file.
640	
641	ADDITIONAL INFORMATION
642	Additional file 1 (docx): Supplementary figures S1-S8. Figure S1: Gold standard gene enrichment by
643	genomic features. Figure S2: Precision and recall of gold standard genes for different genomic features
644	as well as causal candidate prioritization approach. Figure S3: F1 scores for each considered features and
645	prioritization scheme. Figure S4: Enriched colocalizing cell types and tissues by disease categories. Figure
646	S5: Predicted direction of effect of gene expression on disease risk. Figure S6: Concordance between the
647	
	predicted effect of gene expression on disease risk by mendelian randomization (MR) and mechanism of
648	predicted effect of gene expression on disease risk by mendelian randomization (MR) and mechanism of action (MoA) of approved drugs. Figure S7: Association between <i>IL6</i> and diseases, supported by MR,
648 649	predicted effect of gene expression on disease risk by mendelian randomization (MR) and mechanism of action (MoA) of approved drugs. Figure S7: Association between <i>IL6</i> and diseases, supported by MR, colocalization and ABC. Figure S8: Association between <i>IL6R</i> and diseases, supported by MR,
648 649 650	predicted effect of gene expression on disease risk by mendelian randomization (MR) and mechanism of action (MoA) of approved drugs. Figure S7: Association between <i>IL6</i> and diseases, supported by MR, colocalization and ABC. Figure S8: Association between <i>IL6R</i> and diseases, supported by MR, colocalization and ABC.

652 feature and GWAS study source. Table S2: Precision and recall of different features to recover gold

Additional file 2 (xlsx): Supplementary tables S1-S10. Table S1: Enrichment of gold standard genes by

- 653 standard genes. Table S3: Genes with predicted gain or loss of function variants (P<1e-6). Table S4:
- 654 Genes with overrepresented disease categories of GWAS in which they are prioritized as causal. Table
- 655 S5: Genes with overrepresented cell-type colocalizing QTL with GWAS in which they are prioritized as
- 656 causal. Table S6: Significantly enriched colocalizing QTL cell types and tissues in disease GWAS
- 657 categories, after grouping similar tissues and cell-types together. Table S7: Significantly enriched
- 658 colocalizing QTL cell types and tissues in disease GWAS categories, treating each eQTL dataset
- 659 separately. Table S8: Enrichment of prioritized genes by feature across clinical trial phases and approved
- 660 drugs. Table S9: Enrichment of prioritized genes by rank across clinical trial phases and approved drugs.
- Table S10: Causal association between diseases and IL6, IL6ST, or IL6R.
- 662 **Additional file 3: FinnGen banner authors and affiliations.** List of FinnGen authors and their affiliations.
- 663 Additional file 4: Funding statements for eQTL and pQTL datasets. Funding statements and references
- 664 for all eQTL and pQTL datasets used for this manuscript.

665 **REFERENCES**

- Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy Ml, Brown MA, Yang J: **10 Years of GWAS Discovery: Biology, Function, and Translation.** *Am J Hum Genet* 2017, **101**:5-22.
- Loos RJF: 15 years of genome-wide association studies and no signs of slowing down. Nat
 Commun 2020, 11:5900.
- Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A, Morales
 J, Mountjoy E, Sollis E, et al: The NHGRI-EBI GWAS Catalog of published genome-wide
 association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res 2019,
- 47:D1005-D1012.
 Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O,
 O'Connell J, et al: The UK Biobank resource with deep phenotyping and genomic data. Nature
 2018, 562:203-209.
- 5. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray
 M, et al: UK biobank: an open access resource for identifying the causes of a wide range of
 complex diseases of middle and old age. *PLoS Med* 2015, **12**:e1001779.
- 6. Leitsalu L, Haller T, Esko T, Tammesoo ML, Alavere H, Snieder H, Perola M, Ng PC, Magi R, Milani
 681 L, et al: Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu.
 682 Int J Epidemiol 2015, 44:1137-1147.

683 7. Kurki MI, Karjalainen J, Palta P, Sipila TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H, 684 Aavikko M, Kaunisto MA, et al: FinnGen provides genetic insights from a well-phenotyped 685 isolated population. Nature 2023, 613:508-518. 686 8. Laisk T, Lepamets M, Koel M, Abner E, Estonian Biobank Research T, Magi R: Genome-wide 687 association study identifies five risk loci for pernicious anemia. Nat Commun 2021, 12:3761. 688 9. Tyrmi JS, Arffman RK, Pujol-Gualdo N, Kurra V, Morin-Papunen L, Sliz E, FinnGen Consortium 689 EBRT, Piltonen TT, Laisk T, Kettunen J, Laivuori H: Leveraging Northern European population 690 history: novel low-frequency variants for polycystic ovary syndrome. Hum Reprod 2022, 691 **37**:352-365. 692 10. Alver M, Palover M, Saar A, Lall K, Zekavat SM, Tonisson N, Leitsalu L, Reigo A, Nikopensius T, 693 Ainla T, et al: Recall by genotype and cascade screening for familial hypercholesterolemia in a 694 population-based biobank from Estonia. Genet Med 2019, 21:1173-1180. 695 11. King EA, Davis JW, Degner JF: Are drug targets with genetic support twice as likely to be 696 approved? Revised estimates of the impact of genetic support for drug mechanisms on the 697 probability of drug approval. PLoS Genet 2019, 15:e1008489. 698 Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, 12. 699 et al: The support of human genetic evidence for approved drug indications. Nat Genet 2015, 700 47:856-860. 701 13. Reay WR, Cairns MJ: Advancing the use of genome-wide association studies for drug 702 repurposing. Nat Rev Genet 2021, 22:658-671. 703 14. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah 704 T, et al: Association analyses identify 38 susceptibility loci for inflammatory bowel disease and 705 highlight shared genetic risk across populations. Nat Genet 2015, 47:979-986. 706 15. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, 707 Regueiro M, Griffiths A, et al: A genome-wide association study identifies IL23R as an 708 inflammatory bowel disease gene. Science 2006, 314:1461-1463. 709 16. Pidasheva S, Trifari S, Phillips A, Hackney JA, Ma Y, Smith A, Sohn SJ, Spits H, Little RD, Behrens 710 TW, et al: Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor 711 function in the protective genetic variant R381Q. PLoS One 2011, 6:e25038. 712 17. Peyrin-Biroulet L, Ghosh S, Lee SD, Lee WJ, Griffith J, Wallace K, Berg S, Liao X, Panes J, Loftus EV, 713 Jr., Louis E: Effect of risankizumab on health-related quality of life in patients with Crohn's 714 disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Aliment 715 Pharmacol Ther 2023, 57:496-508. 716 18. Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, 717 Hisamatsu T, Lim A, et al: Risankizumab as maintenance therapy for moderately to severely 718 active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-719 controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 2022, 399:2031-2046. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao 720 19. 721 LL, Miao Y, et al: Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N 722 Engl J Med 2016, 375:1946-1960. 723 20. Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, 724 et al: High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. 725 Nat Genet 2012, 44:1336-1340. 726 Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, 21. 727 Ripatti S, Chasman DI, Willer CJ, et al: Biological, clinical and population relevance of 95 loci for 728 blood lipids. Nature 2010, 466:707-713. 729 22. Ober C, Yao TC: The genetics of asthma and allergic disease: a 21st century perspective. 730 Immunol Rev 2011, 242:10-30.

731 23. Valette K, Li Z, Bon-Baret V, Chignon A, Berube JC, Eslami A, Lamothe J, Gaudreault N, Joubert P, 732 Obeidat M, et al: Prioritization of candidate causal genes for asthma in susceptibility loci 733 derived from UK Biobank. Commun Biol 2021, 4:700. 734 24. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, Sandstrom R, 735 Qu H, Brody J, et al: Systematic localization of common disease-associated variation in 736 regulatory DNA. Science 2012, 337:1190-1195. 737 Claussnitzer M, Dankel SN, Kim KH, Quon G, Meuleman W, Haugen C, Glunk V, Sousa IS, Beaudry 25. 738 JL, Puviindran V, et al: FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. N 739 Engl J Med 2015, 373:895-907. 740 26. Mountjoy E, Schmidt EM, Carmona M, Schwartzentruber J, Peat G, Miranda A, Fumis L, Hayhurst 741 J, Buniello A, Karim MA, et al: An open approach to systematically prioritize causal variants and 742 genes at all published human GWAS trait-associated loci. Nat Genet 2021, 53:1527-1533. 743 27. Smith GD, Ebrahim S: 'Mendelian randomization': can genetic epidemiology contribute to 744 understanding environmental determinants of disease? Int J Epidemiol 2003, 32:1-22. 745 28. Davey Smith G, Hemani G: Mendelian randomization: genetic anchors for causal inference in 746 epidemiological studies. Hum Mol Genet 2014, 23:R89-98. 747 29. Richardson TG, Hemani G, Gaunt TR, Relton CL, Davey Smith G: A transcriptome-wide 748 Mendelian randomization study to uncover tissue-dependent regulatory mechanisms across 749 the human phenome. Nat Commun 2020, 11:185. 750 30. Hormozdiari F, van de Bunt M, Segre AV, Li X, Joo JWJ, Bilow M, Sul JH, Sankararaman S, 751 Pasaniuc B, Eskin E: Colocalization of GWAS and eQTL Signals Detects Target Genes. Am J Hum 752 Genet 2016, 99:1245-1260. 753 31. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V: 754 Bayesian test for colocalisation between pairs of genetic association studies using summary 755 statistics. PLoS Genet 2014, 10:e1004383. 756 32. Consortium GT, Laboratory DA, Coordinating Center -Analysis Working G, Statistical Methods 757 groups-Analysis Working G, Enhancing Gg, Fund NIHC, Nih/Nci, Nih/Nhgri, Nih/Nimh, Nih/Nida, 758 et al: Genetic effects on gene expression across human tissues. Nature 2017, 550:204-213. 759 33. Ndungu A, Payne A, Torres JM, van de Bunt M, McCarthy MI: A Multi-tissue Transcriptome 760 Analysis of Human Metabolites Guides Interpretability of Associations Based on Multi-SNP 761 Models for Gene Expression. Am J Hum Genet 2020, 106:188-201. 762 34. Liu X, Finucane HK, Gusev A, Bhatia G, Gazal S, O'Connor L, Bulik-Sullivan B, Wright FA, Sullivan 763 PF, Neale BM, Price AL: Functional Architectures of Local and Distal Regulation of Gene 764 Expression in Multiple Human Tissues. Am J Hum Genet 2017, 100:605-616. 765 35. Consortium GT: Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: 766 multitissue gene regulation in humans. Science 2015, 348:648-660. 767 36. Connally NJ, Nazeen S, Lee D, Shi H, Stamatoyannopoulos J, Chun S, Cotsapas C, Cassa CA, 768 Sunyaev SR: The missing link between genetic association and regulatory function. Elife 2022, 769 11. Mostafavi H, Spence JP, Naqvi S, Pritchard JK: Limited overlap of eQTLs and GWAS hits due to 770 37. 771 systematic differences in discovery. bioRxiv 2022. 772 38. Lessard S, Gatof ES, Beaudoin M, Schupp PG, Sher F, Ali A, Prehar S, Kurita R, Nakamura Y, Baena 773 E, et al: An erythroid-specific ATP2B4 enhancer mediates red blood cell hydration and malaria 774 susceptibility. J Clin Invest 2017, 127:3065-3074. 775 39. Smemo S, Tena JJ, Kim KH, Gamazon ER, Sakabe NJ, Gomez-Marin C, Aneas I, Credidio FL, 776 Sobreira DR, Wasserman NF, et al: Obesity-associated variants within FTO form long-range 777 functional connections with IRX3. Nature 2014, 507:371-375.

778 40. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, 779 Langdon R, et al: The MR-Base platform supports systematic causal inference across the 780 human phenome. Elife 2018, 7. 781 41. Nasser J, Bergman DT, Fulco CP, Guckelberger P, Doughty BR, Patwardhan TA, Jones TR, Nguyen 782 TH, Ulirsch JC, Lekschas F, et al: Genome-wide enhancer maps link risk variants to disease 783 genes. Nature 2021, 593:238-243. 784 42. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F: The 785 Ensembl Variant Effect Predictor. Genome Biol 2016, 17:122. 786 43. Loh PR, Danecek P, Palamara PF, Fuchsberger C, Y AR, H KF, Schoenherr S, Forer L, McCarthy S, 787 Abecasis GR, et al: Reference-based phasing using the Haplotype Reference Consortium panel. 788 Nat Genet 2016, 48:1443-1448. 789 44. Browning SR, Browning BL: Rapid and accurate haplotype phasing and missing-data inference 790 for whole-genome association studies by use of localized haplotype clustering. Am J Hum 791 Genet 2007, 81:1084-1097. 792 team P-U: https://pan.ukbb.broadinstitute.org. 2020. 45. 793 46. Maintainer BP: liftOver: Changing genomic coordinate systems with rtracklayer::liftOver. R 794 package version 1180 2021. 795 47. Stein D, Bayrak ÇS, Wu Y, Stenson PD, Cooper DN, Schlessinger A, Itan Y: Genome-wide 796 prediction of pathogenic gain- and loss-of-function variants from ensemble learning of diverse 797 feature set. bioRxiv 2022. 798 48. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, 799 Cooper DN: Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003, 21:577-800 581. 801 49. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, 802 Surendran P, et al: Genomic atlas of the human plasma proteome. Nature 2018, 558:73-79. 803 50. Chen L, Ge B, Casale FP, Vasquez L, Kwan T, Garrido-Martin D, Watt S, Yan Y, Kundu K, Ecker S, et 804 al: Genetic Drivers of Epigenetic and Transcriptional Variation in Human Immune Cells. Cell 805 2016, 167:1398-1414 e1324. 806 51. Vosa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, Kirsten H, Saha A, Kreuzhuber 807 R, Yazar S, et al: Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and 808 polygenic scores that regulate blood gene expression. Nat Genet 2021, 53:1300-1310. 809 52. Kerimov N, Hayhurst JD, Peikova K, Manning JR, Walter P, Kolberg L, Samovica M, Sakthivel MP, 810 Kuzmin I, Trevanion SJ, et al: A compendium of uniformly processed human gene expression 811 and splicing quantitative trait loci. Nat Genet 2021, 53:1290-1299. 812 53. Buil A, Brown AA, Lappalainen T, Vinuela A, Davies MN, Zheng HF, Richards JB, Glass D, Small KS, 813 Durbin R, et al: Gene-gene and gene-environment interactions detected by transcriptome 814 sequence analysis in twins. Nat Genet 2015, 47:88-91. 815 54. Jaffe AE, Straub RE, Shin JH, Tao R, Gao Y, Collado-Torres L, Kam-Thong T, Xi HS, Quan J, Chen Q, 816 et al: Developmental and genetic regulation of the human cortex transcriptome illuminate 817 schizophrenia pathogenesis. Nat Neurosci 2018, 21:1117-1125. 818 55. Schmiedel BJ, Singh D, Madrigal A, Valdovino-Gonzalez AG, White BM, Zapardiel-Gonzalo J, Ha B, 819 Altay G, Greenbaum JA, McVicker G, et al: Impact of Genetic Polymorphisms on Human 820 Immune Cell Gene Expression. Cell 2018, 175:1701-1715 e1716. 821 56. Ng B, White CC, Klein HU, Sieberts SK, McCabe C, Patrick E, Xu J, Yu L, Gaiteri C, Bennett DA, et 822 al: An xQTL map integrates the genetic architecture of the human brain's transcriptome and 823 epigenome. Nat Neurosci 2017, 20:1418-1426.

824 57. Gutierrez-Arcelus M, Lappalainen T, Montgomery SB, Buil A, Ongen H, Yurovsky A, Bryois J, Giger 825 T, Romano L, Planchon A, et al: Passive and active DNA methylation and the interplay with 826 genetic variation in gene regulation. Elife 2013, 2:e00523. 827 58. van de Bunt M, Manning Fox JE, Dai X, Barrett A, Grey C, Li L, Bennett AJ, Johnson PR, Rajotte 828 RV, Gaulton KJ, et al: Transcript Expression Data from Human Islets Links Regulatory Signals 829 from Genome-Wide Association Studies for Type 2 Diabetes and Glycemic Traits to Their 830 Downstream Effectors. PLoS Genet 2015, 11:e1005694. 831 59. Alasoo K, Rodrigues J, Mukhopadhyay S, Knights AJ, Mann AL, Kundu K, Consortium H, Hale C, 832 Dougan G, Gaffney DJ: Shared genetic effects on chromatin and gene expression indicate a role 833 for enhancer priming in immune response. Nat Genet 2018, 50:424-431. 834 60. Taylor DL, Jackson AU, Narisu N, Hemani G, Erdos MR, Chines PS, Swift A, Idol J, Didion JP, Welch 835 RP, et al: Integrative analysis of gene expression, DNA methylation, physiological traits, and 836 genetic variation in human skeletal muscle. Proc Natl Acad Sci U S A 2019, **116**:10883-10888. 837 61. Lepik K, Annilo T, Kukuskina V, e QC, Kisand K, Kutalik Z, Peterson P, Peterson H: C-reactive 838 protein upregulates the whole blood expression of CD59 - an integrative analysis. PLoS 839 Comput Biol 2017, 13:e1005766. 840 62. Quach H, Rotival M, Pothlichet J, Loh YE, Dannemann M, Zidane N, Laval G, Patin E, Harmant C, 841 Lopez M, et al: Genetic Adaptation and Neandertal Admixture Shaped the Immune System of 842 Human Populations. Cell 2016, 167:643-656 e617. 843 63. Nedelec Y, Sanz J, Baharian G, Szpiech ZA, Pacis A, Dumaine A, Grenier JC, Freiman A, Sams AJ, 844 Hebert S, et al: Genetic Ancestry and Natural Selection Drive Population Differences in 845 Immune Responses to Pathogens. Cell 2016, 167:657-669 e621. 846 64. Panopoulos AD, D'Antonio M, Benaglio P, Williams R, Hashem SI, Schuldt BM, DeBoever C, Arias 847 AD, Garcia M, Nelson BC, et al: iPSCORE: A Resource of 222 iPSC Lines Enabling Functional 848 Characterization of Genetic Variation across a Variety of Cell Types. Stem Cell Reports 2017, 849 8:1086-1100. 850 Pashos EE, Park Y, Wang X, Raghavan A, Yang W, Abbey D, Peters DT, Arbelaez J, Hernandez M, 65. 851 Kuperwasser N, et al: Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like 852 Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci. Cell Stem Cell 2017, 853 20:558-570 e510. 854 66. Kilpinen H, Goncalves A, Leha A, Afzal V, Alasoo K, Ashford S, Bala S, Bensaddek D, Casale FP, 855 Culley OJ, et al: Common genetic variation drives molecular heterogeneity in human iPSCs. 856 Nature 2017, 546:370-375. 857 67. Lappalainen T, Sammeth M, Friedlander MR, t Hoen PA, Monlong J, Rivas MA, Gonzalez-Porta 858 M, Kurbatova N, Griebel T, Ferreira PG, et al: Transcriptome and genome sequencing uncovers 859 functional variation in humans. Nature 2013, 501:506-511. 860 68. Hoffman GE, Bendl J, Voloudakis G, Montgomery KS, Sloofman L, Wang YC, Shah HR, Hauberg 861 ME, Johnson JS, Girdhar K, et al: CommonMind Consortium provides transcriptomic and epigenomic data for Schizophrenia and Bipolar Disorder. Sci Data 2019, 6:180. 862 863 69. Guelfi S, D'Sa K, Botia JA, Vandrovcova J, Reynolds RH, Zhang D, Trabzuni D, Collado-Torres L, 864 Thomason A, Quijada Leyton P, et al: Regulatory sites for splicing in human basal ganglia are 865 enriched for disease-relevant information. Nat Commun 2020, 11:1041. 70. 866 Young AMH, Kumasaka N, Calvert F, Hammond TR, Knights A, Panousis N, Park JS, Schwartzentruber J, Liu J, Kundu K, et al: A map of transcriptional heterogeneity and regulatory 867 868 variation in human microglia. Nat Genet 2021, 53:861-868. 869 71. Consortium GT: The GTEx Consortium atlas of genetic regulatory effects across human tissues. 870 Science 2020, 369:1318-1330.

871	72.	Theusch E, Chen YI, Rotter JI, Krauss RM, Medina MW: Genetic variants modulate gene
872		expression statin response in human lymphoblastoid cell lines. BMC Genomics 2020, 21:555.
873	73.	Peng S, Deyssenroth MA, Di Narzo AF, Cheng H, Zhang Z, Lambertini L, Ruusalepp A, Kovacic JC,
874		Bjorkegren JLM, Marsit CJ, et al: Genetic regulation of the placental transcriptome underlies
875		birth weight and risk of childhood obesity. PLoS Genet 2018, 14:e1007799.
876	74.	Steinberg J, Southam L, Roumeliotis TI, Clark MJ, Jayasuriya RL, Swift D, Shah KM, Butterfield NC,
877		Brooks RA, McCaskie AW, et al: A molecular quantitative trait locus map for osteoarthritis. Nat
878		Commun 2021, 12 :1309
879	75.	Schwartzentruber J, Foskolou S, Kilpinen H, Rodrigues J, Alasoo K, Knights AJ, Patel M, Goncalves
880		A, Ferreira R, Benn CL, et al: Molecular and functional variation in iPSC-derived sensory
881		neurons. <i>Nat Genet</i> 2018, 50 :54-61.
882	76.	Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ: Second-generation PLINK: rising to
883		the challenge of larger and richer datasets. Gigascience 2015, 4:7.
884	77.	Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini
885		JL, McCarthy S, McVean GA, Abecasis GR: A global reference for human genetic variation.
886		Nature 2015, 526: 68-74.
887	78.	Ghoussaini M, Mountjoy E, Carmona M, Peat G, Schmidt EM, Hercules A, Fumis L, Miranda A,
888		Carvalho-Silva D, Buniello A, et al: Open Targets Genetics: systematic identification of trait-
889		associated genes using large-scale genetics and functional genomics. Nucleic Acids Res 2021,
890		49: D1311-D1320.
891	79.	King EA, Dunbar F, Davis JW, Degner JF: Estimating colocalization probability from limited
892		summary statistics. BMC Bioinformatics 2021, 22:254.
893	80.	Lin D: An Information-Theoretic Definition of Similarity. In Proceedings of the Fifteenth
894		International Conference on Machine Learning. pp. 296–304: Morgan Kaufmann Publishers Inc.;
895		1998:296–304.
896	81.	Resnik P: Semantic similarity in a taxonomy: an information-based measure and its application
897		to problems of ambiguity in natural language. 1999, 11 :95–130.
898	82.	Greene D, Richardson S, Turro E: ontologyX: a suite of R packages for working with ontological
899		data. Bioinformatics 2017, 33:1104-1106.
900	83.	Boughton AP, Welch RP, Flickinger M, VandeHaar P, Taliun D, Abecasis GR, Boehnke M:
901		LocusZoom.js: interactive and embeddable visualization of genetic association study results.
902		Bioinformatics 2021, 37: 3017-3018.
903	84.	Wang G, Sarkar A, Carbonetto P, Stephens M: A simple new approach to variable selection in
904		regression, with application to genetic fine mapping. J R Stat Soc Series B Stat Methodol 2020,
905		82: 1273-1300.
906	85.	Nicolas G, Wallon D, Charbonnier C, Quenez O, Rousseau S, Richard AC, Rovelet-Lecrux A,
907		Coutant S, Le Guennec K, Bacq D, et al: Screening of dementia genes by whole-exome
908		sequencing in early-onset Alzheimer disease: input and lessons. Eur J Hum Genet 2016, 24:710-
909		716.
910	86.	Laurin N, Brown JP, Morissette J, Raymond V: Recurrent mutation of the gene encoding
911		sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002, 70:1582-1588.
912	87.	Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Jr.,
913		Ellis MC, Fullan A, et al: A novel MHC class I-like gene is mutated in patients with hereditary
914		haemochromatosis. Nat Genet 1996, 13:399-408.
915	88.	Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P,
916		Gudbjartsson D, Maloney J, et al: A mutation in APP protects against Alzheimer's disease and
917		age-related cognitive decline. Nature 2012, 488:96-99.

918	89.	Kristjansson RP, Benonisdottir S, Davidsson OB, Oddsson A, Tragante V, Sigurdsson JK,
919		Stefansdottir L, Jonsson S, Jensson BO, Arthur JG, et al: A loss-of-function variant in ALOX15
920		protects against nasal polyps and chronic rhinosinusitis. Nat Genet 2019, 51:26/-2/6.
921	90.	Morris AP, Le TH, Wu H, Akbarov A, van der Most PJ, Hemani G, Smith GD, Mahajan A, Gaulton
922		KJ, Nadkarni GN, et al: Trans-ethnic kidney function association study reveals putative causal
923		genes and effects on kidney-specific disease aetiologies. Nat Commun 2019, 10 :29.
924	91.	Beaudoin M, Gupta RM, Won HH, Lo KS, Do R, Henderson CA, Lavoie-St-Amour C, Langlois S,
925		Rivas D, Lehoux S, et al: Myocardial Infarction-Associated SNP at 6p24 Interferes With MEF2
926		Binding and Associates With PHACTR1 Expression Levels in Human Coronary Arteries.
927		Arterioscler Thromb Vasc Biol 2015, 35: 1472-1479.
928	92.	Lopez-Isac E, Smith SL, Marion MC, Wood A, Sudman M, Yarwood A, Shi C, Gaddi VP, Martin P,
929		Prahalad S, et al: Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes
930		identifies novel risk loci, target genes and key regulatory mechanisms. Ann Rheum Dis 2021,
931		80: 321-328.
932	93.	Yang J, McGovern A, Martin P, Duffus K, Ge X, Zarrineh P, Morris AP, Adamson A, Fraser P,
933		Rattray M, Eyre S: Analysis of chromatin organization and gene expression in T cells identifies
934		functional genes for rheumatoid arthritis. Nat Commun 2020, 11:4402.
935	94.	Dasgupta B, Unizony S, Warrington KJ, Sloane Lazar J, Giannelou A, Nivens C, Akinlade B, Wong
936		W, Lin Y, Buttgereit F, et al: LB0006 SARILUMAB IN PATIENTS WITH RELAPSING POLYMYALGIA
937		RHEUMATICA: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO
938		CONTROLLED TRIAL (SAPHYR). Annals of the Rheumatic Diseases 2022, 81:210-211.
939	95.	Kanai M, Elzur R, Zhou W, Global Biobank Meta-analysis I, Daly MJ, Finucane HK: Meta-analysis
940		fine-mapping is often miscalibrated at single-variant resolution. Cell Genom 2022, 2 .
941	96.	Hormozdiari F, Zhu A, Kichaev G, Ju CJ, Segre AV, Joo JWJ, Won H, Sankararaman S, Pasaniuc B,
942		Shifman S, Eskin E: Widespread Allelic Heterogeneity in Complex Traits. Am J Hum Genet 2017,
943		100 :789-802.
944	97.	Zhu A, Matoba N, Wilson EP, Tapia AL, Li Y, Ibrahim JG, Stein JL, Love MI: MRLocus: Identifying
945		causal genes mediating a trait through Bayesian estimation of allelic heterogeneity. <i>PLoS</i>
946		Genet 2021, 17 :e1009455.
947	98.	Yin X, Bose D, Kwon A, Hanks SC, Jackson AU, Stringham HM, Welch R, Oravilahti A, Fernandes
948		Silva L, FinnGen, et al: Integrating transcriptomics, metabolomics, and GWAS helps reveal
949		molecular mechanisms for metabolite levels and disease risk. Am J Hum Genet 2022, 109:1727-
950		1741.